Greyson International Inc. Receives Industry Expert Validation Regarding
Pharmaceutical Patent Cliff Panic
COCONUT CREEK, Fla. -- July 22, 2013
Greyson International Inc. (OTC Pink Sheets: GYSN), developer of an innovative
patented topical delivery technology targeting the multi-billion dollar
cosmetics and OTC pharmaceutical industries, today announced that talks with
patent law firm Lerner Greenberg Stemer LLP resulted in across the board
agreement with Greyson’s plan to help save and stave the potential $90+
billion loss in the pharmaceutical market.
Large pharmaceutical companies are facing a so-called “patent cliff”, whereby
brand names drugs, once having delivered steady sales and profits are losing,
or have already lost, their patent protection. Johnson and Johnson (NYSE:JNJ)
has had three blockbuster drug patents expire in the last two years, Eli
Lilly’s (NYSE:LLY) Cymbalta loses its patent at the end of 2013, and Pfizer
(NYSE:PFE) recently attained a short extension on multibillion-dollar Celebrex
which expires in Dec. 2015.
Lerner Greenberg Stemer LLP patent law firm for the world’s largest
multinational corporations concur with Greyson’s plan to utilize their
patented Trilexon® trans-dermal topical delivery system in several ways.
“Leveraging our technology, large pharmaceutical companies can potentially
reformulate their drugs to be delivered topically instead of orally, extend
patent lives, and/or create new patents quickly under the Greyson umbrella”
said Harvey Tauman, CEO of Greyson International Inc. “Greyson International,
in addition to being debt free, has invested millions over a period of about
20 years culminating to the point whereby preparation is meeting opportunity.”
Currently Greyson International has anchored a large manufacturer, added two
prominent physicians as consultants, and recruited top industry beauty
consultants for Greyson Skincare® with Trilexon® technology. Their new
spokesperson and brand manager, Tia Castle is preparing to launch Greyson
Skincare line on network shopping television toward the fourth quarter of
2013. Greyson is open to adding new talent to the managerial team as it
rapidly expands to meet market demands. All inquiries may contact Harvey
Greyson International’s revolutionary patented Trilexon® delivery system
allows the finest ingredients to be released topically over an extended period
of time, while maintaining the skin’s natural intracellular barrier to promote
natural moisture and lipid levels, providing a comfortable and durable
experience that’s unlike anything else in the market.
About Greyson International, Inc.
Greyson’s primary focus is on its recently patented Trilexon® delivery system.
In addition to cosmetic applications, Trilexon® may also have benefits in the
medical field where it is important to deliver active ingredients. Trilexon®
is a registered trademark of Greyson International Inc. For more information,
visit our website;http://greysonintl.com and join the Greyson International's
This release contains information about management’s view of our future
expectations, plans and prospects that constitute forward-looking statements
for purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
historical results or those indicated by these forward-looking statements as a
result of a variety of factors including, but not limited to, risks and
uncertainties associated with our financial condition, our ability to sell our
products and our ability to compete with competitors. We encourage you to
review other factors that may affect our future results on any current or
future documents we file periodically with the Securities & Exchange
Greyson International Inc.
Harvey Tauman, 954-482-0497, Harvey@greysonintl.com
Chief Executive Officer
Press spacebar to pause and continue. Press esc to stop.